KMID : 0311120200610070597
|
|
Yonsei Medical Journal 2020 Volume.61 No. 7 p.597 ~ p.605
|
|
Determinants and Clinical Outcomes of Extended Dual Antiplatelet Therapy over 3 Years after Drug-Eluting Stent Implantation: A Retrospective Analysis
|
|
Lee Oh-Hyun
Kim Byeong-Keuk Hong Sung-Jin Kim Seung-Hwan Ahn Chul-Min Shin Dong-Ho Kim Jung-Sun Kang Tae-Soo Ko Young-Guk Choi Dong-Hoon Hong Myeong-Ki Jang Yang-Soo
|
|
Abstract
|
|
|
Purpose: Although current guidelines recommend the administration of dual antiplatelet therapy (DAPT) for up to 12 months after the implantation of a drug-eluting stent (DES), extended DAPT is frequently used in real-world practice.
Materials and Methods: From the Korean Multicenter Angioplasty Team registry, we identified a total of 1414 patients who used DAPT for >3 years after DES implantation (extended-DAPT group) and conducted a landmark analysis at 36 months after the index procedure. We evaluated the determinants for and long-term outcomes of extended DAPT and compared the occurrence of major adverse cardiovascular and cerebrovascular events (MACCE), defined as the composite of all-cause death, myocardial infarction, stent thrombosis, and stroke, between the extended-DAPT group and the guideline-DAPT group [DAPT <1 year after DES implantation (n=1273)].
Results: Multivariate analysis indicated the occurrence of acute coronary syndrome as the most significant clinical determinant of the use of extended DAPT. Bifurcation, stent diameter ¡Â3.0 mm, total stented length ¡Ã28 mm, and use of first-generation DESs were also significant angiographic and procedural determinants. MACCE rates were similar between the extended-DAPT group and the guideline-DAPT group in crude analysis [hazard ratio (HR), 1.08; 95% confidence interval (CI), 0.69?1.68; p=0.739] and after propensity matching (HR, 1.22; 95% CI, 0.72?2.07; p=0.453). Major bleeding rates were comparable between the two groups.
Conclusion: In patients undergoing percutaneous coronary intervention, indefinite use of DAPT does not show superior outcomes to those of guideline-DAPT. Major bleeding rates are also similar.
|
|
KEYWORD
|
|
Antiplatelet therapy, drug-eluting stent, percutaneous coronary intervention
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|
|